FutureFuel Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FF research report →
Price Chart
About the company
Operating through its subsidiary, FutureFuel Chemical Company, FutureFuel Corp. manufactures and distributes a broad spectrum of chemical products across the United States, encompassing both bio-based fuels and specialized bio-based chemicals. The enterprise is structured into two principal business segments: Chemicals and Biofuels.
- CEO
- Roeland H. Polet
- IPO
- 2011
- Employees
- 493
- HQ
- Batesville, AR, US
Get TickerSpark's AI analysis on FF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $128.52M
- P/E
- -4.41
- Fwd P/E
- 3.66
- PEG
- 0.21
- P/S
- 0.56
- P/B
- 0.92
- EV/EBITDA
- -5.08
- Div Yield
- 4.67%
- Gross Margin
- -1.93%
- Op Margin
- -8.48%
- Net Margin
- -12.59%
- ROE
- -19.93%
- ROIC
- -11.22%
Latest fiscal year · YoY change
- Revenue
- $95.74M-60.7%
- Gross Profit
- $-40,689,000-307.1%
- Op Income
- $-54,254,000
- Net Income
- $-49,397,000-418.6%
- EPS
- $-1.13-422.9%
- OCF Growth
- -215.9%
- FCF Growth
- -553.7%
- 52W High
- $6.99
- 52W Low
- $2.62
- 50D MA
- $5.01
- 200D MA
- $4.63
- Beta
- 0.97
- RSI (14)
- 20
- Avg Volume
- 603.19K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
FutureFuel posted sharply higher revenue on strong biofuel sales and gave upbeat 2027 commentary, but Q3 still showed a gross loss and negative EBITDA because elevated input and derivative costs outweighed the volume gains.· November 10, 2026
- Revenue rose to $104.7 million, up 361.3% year over year, driven mainly by biofuel pricing and volume.
- Third quarter gross loss improved to $5.4 million from $6.5 million last year, while adjusted EBITDA was a $4.9 million loss versus a $5.3 million loss.
- Biofuel utilization reached 83%, and management said demand is strong with Q4 orders already booked for more than 9% of fourth-quarter biodiesel capacity.
- Chemicals was hit by customer turnarounds and inventory actions, but management expects no major planned maintenance through Q1 2027 and stronger utilization in Q4.
- Management highlighted reshoring wins, including a new European customer expected to start initial batch production in Q1 2027 and reach full rates mid-2027.
Third-quarter revenue was $104.7 million, up 361.3% from $22.7 million a year ago. Gross loss was $5.4 million versus a gross loss of $6.5 million in the prior-year quarter; net loss was $8.4 million versus $9.2 million, and adjusted EBITDA was a loss of $4.9 million versus a $5.3 million loss. Chemicals revenue was $16.9 million, up 8.6%, and Biofuel revenue was $87.8 million versus $7.1 million last year. Biofuel gross loss was $9.8 million versus $2.4 million, while Chemicals gross profit was $4.4 million versus a $4.1 million loss. Management said $8.7 million of net derivative losses hit Q3 results, including $2.3 million tied to physical inventory expected to be recovered in Q4, and $1.5 million of internally generated RINs will benefit Q4 when sold. Cash and equivalents were $21.3 million at September 30, down from $34.3 million at June 30, with no borrowings on the $35 million revolver. For Q4 and into 2027, management expects biofuel demand to stay strong, Q4 chemical utilization to be above prior year levels, no major planned maintenance through Q1 2027, and incremental contributions from reshoring, customer-funded growth projects, and a glycerin upgrade opportunity worth an estimated $5 million to $10 million beginning in 2027.
Roeland Polet framed the quarter as a split story: exceptional biofuel operating performance on one side, and temporary chemical segment disruptions on the other. He said the company is seeing more inquiries from European chemical producers looking to reshore to the U.S., and described that as a potentially larger long-term opportunity than even prior reshoring activity from China and India. He also emphasized a strategy centered on commercial growth, operational excellence, and returns-driven capital allocation, while noting the business is entering a stronger phase heading into 2027.
Rose Sparks focused on the reported numbers and balance sheet. She said revenue increased 361.3% to $104.7 million, gross loss improved to $5.4 million, net loss narrowed to $8.4 million, and adjusted EBITDA loss improved to $4.9 million. She also noted $8.7 million of net derivative losses in the quarter, $21.3 million of cash at quarter-end, no revolver borrowings, $10.3 million of operating cash usage, and $3.3 million of capex, including $2.7 million of discretionary spending.
Analysts pressed management on the new European reshoring opportunity, asking how it came about and what it could mean. Management said European customers are increasingly approaching FutureFuel because production overseas is becoming uneconomic, and it expects this customer to start in Q1 2027 and ramp to full production by mid-2027. Questions also focused on elevated input costs and Q3 margin pressure; management said soy oil and other inputs remain high but are moderating, and cited a timing benefit from $2.3 million of derivatives and $1.5 million of RIN sales in Q4. On 2027 margins, management said Q3 was atypical because of turnarounds and a customer inventory adjustment, and pointed to higher utilization, customer-funded investments, and added capacity as drivers of improvement.
The call suggested stronger operating momentum into Q4 and 2027, with biofuel utilization at 83%, strong order visibility, and no major planned maintenance through Q1 2027. Management also pointed to multiple growth levers: reshoring opportunities, customer-funded expansions, glycerin upgrading, and higher utilization at existing assets.
Despite the revenue surge, the company still reported a gross loss and adjusted EBITDA loss because elevated feedstock costs and derivative losses offset the operating gains. Cash fell to $21.3 million, operating cash flow was negative, and management said it intends to be measured on buybacks or dividend increases until the balance sheet is rebuilt toward $50 million.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 59.1%
- Shares Outstanding
- 43.86M
- Float Shares
- 25.93M
of shares held by institutions
112 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for FF, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 1.98M | ▲ 64.61K |
| Vanguard Group Inc | 1.43M | ▲ 20.49K |
| Dimensional Fund Advisors LP | 1.43M | ▼ 5.59K |
| Renaissance Technologies LLC | 1.39M | ▼ 42.38K |
| Ameriprise Financial Inc | 1.32M | ▲ 1.21M |
| Vanguard Capital Management LLC | 1.14M | 0 |
| Two Sigma Investments, LP | 782.08K | ▼ 46.00K |
| Geode Capital Management, LLC | 631.46K | ▼ 29.44K |
| State Street Corp | 622.28K | ▲ 1.86K |
| Citadel Advisors LLC | 540.99K | ▲ 154.34K |
| Bridgeway Capital Management, LLC | 473.29K | ▼ 5.13K |
| Morgan Stanley | 459.09K | ▲ 154.42K |
Held by 119 ETFs
Biggest fund positions in FF by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | 222 Capital, U/I dated March 25, 2003 | other | 0 |
| Nov 13, 26 | Novelly Paul Anthony II | other | 17,085,100 |
| Nov 12, 26 | Bedell Donald C. | buy | 40,000 |
| Nov 12, 26 | Butcher Pamela R | buy | 10,000 |
| Nov 12, 26 | Polet Roeland | buy | 48,080 |
| Nov 12, 26 | SPARKS ROSE | buy | 10,750 |
| Jun 4, 26 | Polet Roeland | buy | 10,000 |
| Mar 18, 26 | KRUSZEWSKI RONALD J | other | 10,000 |
| Mar 18, 26 | Rowe Richard P. | other | 10,000 |
| Mar 18, 26 | Manheim Paul | other | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FF coverage
Recent articles, reports, and earnings notes.
No research on FF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FF report →Faraday Future Founder and Global CEO YT Jia Shares Weekly Updates on Robots Delivery to Central Michigan University, Brain Blocks AI Module, and Industrial Scenario Validation
gurufocus.com · Nov 15
FutureFuel Corp. (FF) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
What FutureFuel (FF) Said on Its Q3 Earnings Call
marketbeat.com · Nov 10
FutureFuel Announces Third Quarter 2026 Results
globenewswire.com · Nov 9
FUTUREFUEL ANNOUNCES THIRD QUARTER 2026 RESULTS CONFERENCE CALL AND WEBCAST DATE
globenewswire.com · Oct 27
FFR to Hold Listing Ceremony and Investor Day on October 26; FFAI Announces Rescheduling of YT Jia's Investor Weekly Report to October 26
gurufocus.com · Oct 25
Faraday Future Announces YT Jia's Investor Weekly Report Rescheduled to October 26; FFR to Hold Listing Ceremony and Investor Day on October 26
gurufocus.com · Oct 25
Faraday Future Announces Details for FFR's Listing Ceremony and Nasdaq Investor Day, Taking Place on Monday, Oct. 26 at Nasdaq's Market site in NYC
gurufocus.com · Oct 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.